Comments on: Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Comments on: Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN https://thegbm.com/novartis-fabhalta-iptacopan-receives-fda-traditional-approval-as-first-and-only-complement-inhibitor-to-significantly-slow-kidney-function-decline-in-primary-igan/ Business news, opinion, reviews, interviews Thu, 16 Jul 2026 23:02:00 +0000 hourly 1 https://wordpress.org/?v=7.0.1